BridgeMD
First-line immunotherapy using Wilms’ tumor protein 1 (WT1)-targeted dendritic cell vaccinations for malignant pleural mesothelioma
EU CTIS ID: 2024-517970-35-00
What this study is testing
To evaluate the feasibility and safety of Wilms' tumor 1 mRNA-electroporated dendritic cell (DC) vaccinations in patients with malignant pleural mesothelioma (MPM) as first-line treatment combined with standard chemotherapy
- Therapeutic exploratory (Phase II)
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- Diagnosis with histologically proven epithelial MPM
- Age: ≥18 years at the time of enrollment
- WHO performance status 0–1 at the time of enrollment
- Fit to undergo general anesthesia, a thoracoscopy, leukapheresis, chemotherapy, immunotherapy and (in case of resectable disease) P/D
- No history of receiving any investigational treatment within 28 days of study enrollment
- No history of intolerance to pemetrexed and/or cisplatin
You likely can't join if
- Unwilling or unable to comply with the study requirements
- Prior treatment for mesothelioma
- History of other malignancy within the last five years, except for non-melanoma skin cancer and cervical carcinoma in situ or unless the investigator rationalizes otherwise
- Known proven metastases
- Known concomitant presence of any immunosuppressive disease (e.g. HIV) or any active autoimmune condition, except for vitiligo
- Pregnant or breastfeeding
See the full eligibility criteria
- Diagnosis with histologically proven epithelial MPM
- Age: ≥18 years at the time of enrollment
- WHO performance status 0–1 at the time of enrollment
- Fit to undergo general anesthesia, a thoracoscopy, leukapheresis, chemotherapy, immunotherapy and (in case of resectable disease) P/D
- No history of receiving any investigational treatment within 28 days of study enrollment
- No history of intolerance to pemetrexed and/or cisplatin
- Before patient registration written informed consent must be given according to ICH/GCP, and national/local regulations
- Unwilling or unable to comply with the study requirements
- Prior treatment for mesothelioma
- History of other malignancy within the last five years, except for non-melanoma skin cancer and cervical carcinoma in situ or unless the investigator rationalizes otherwise
- Known proven metastases
- Known concomitant presence of any immunosuppressive disease (e.g. HIV) or any active autoimmune condition, except for vitiligo
- Pregnant or breastfeeding
The study team makes the final eligibility decision.
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 65+ years, 18-64 years. The study team makes the final eligibility decision.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.